Details of the Drug
General Information of Drug (ID: DM83951)
Drug Name |
AG-E-85378
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide; 269390-69-4; VEGFR Tyrosine Kinase Inhibitor II; VEGF Receptor Tyrosine Kinase Inhibitor II; CHEMBL101683; 3hng; AG-E-85378; ZINC8732; SCHEMBL3005186; GTPL6056; N-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide; CTK4F8762; DTXSID60430900; MolPort-044-561-457; HMS3229O07; IN1017; BDBM50132151; AKOS030580576; DB07288; CCG-206804; NCGC00387770-01; ACM269390694; RT-016223; KB-299355; J-016613; N-(4-Chlorophenyl)-2-(4-pyridinylmethylamino)benzamide
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL is unavailable | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 337.8 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 4.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References